What is King Pharmaceuticals's accrued investment income?

King Pharmaceuticals (KG) reported accrued investment income of $4.87M in Q1 2026.

What does accrued investment income mean?

This represents interest, dividends, or other investment returns that have been earned by the company but have not yet been received in cash. It serves as a bridge between accrual-based accounting and actual cash inflows from the investment portfolio. A significant increase may indicate a timing delay in cash collection or a shift in the composition of the investment portfolio.

King Pharmaceuticals KG Accrued investment income

Accrued investment income at other companies

Arch Capital GroupACGL

$302M+13.1%

Everest GroupEG

$389M-0.5%

SiriusPointSPNT

$41.4M-1.7%

Selective Insurance GroupSIGI

$93.74M+21.6%

Reinsurance Group of AmericaRGA

$1.36B+28.5%

W.R. BerkleyWRB

$246.02M+4.0%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedInvestmentIncomeReceivable.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's accrued investment income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's accrued investment income?: King Pharmaceuticals (KG) reported accrued investment income of $4.87M in Q1 2026.
What does accrued investment income mean?: This represents interest, dividends, or other investment returns that have been earned by the company but have not yet been received in cash. It serves as a bridge between accrual-based accounting and actual cash inflows from the investment portfolio. A significant increase may indicate a timing delay in cash collection or a shift in the composition of the investment portfolio.